Psyence Biomedical (PBM) Equity Income (2026)
Psyence Biomedical (PBM) posted Equity Income of -$45239.0 for Q1 2026.
Powered by 
Analysis
Psyence Biomedical (PBM) Equity Income (2026) Analysis & Trends
Psyence Biomedical has reported Equity Income for 1 years, with the latest figure at -$45239.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.75 Bn | 193.77 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.04 Bn | 175.86 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.26 Bn | 123.41 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.82 Bn | 73.83 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.17 Bn | 55.99 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.03 Bn | 47.89 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.36 Bn | 30.05 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.73 Bn | 30.44 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.36 Bn | 29.36 Bn | 1.16 Mn | - |
| 10 | Psyence Biomedical | 2.62 Mn | 2.62 Mn | - | -45,239.00 |